Home

RA Capital Healthcare Fund II, L.P.

CIK 1392402 · last filed 2009-05-11

RA Capital Healthcare Fund II, L.P. is a corporate insider who has filed 5 SEC Form 4 insider transactions across 2 companies since 2008. The most recent filing shows the insider bought $1.2M of BSTC on May 11, 2009. Across all open-market trades the lifetime net is +$8.8M, making them a net buyer over the disclosed history. The firm reports its address in Boston, MA. 42 SEC filings were submitted jointly with Peter Kolchinsky.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

2

Total Filings

5

Lifetime Open-Market Net

$8.76M

Filer Profile

Reported Address
800 BOYLSTON STREET
SUITE 1500
BOSTON, MA 02199
Phone
(617) 778-2500
State of Incorporation
MA
Formerly Known As
RA Capital Biotech Fund II, L.P. (2007–2008)
Related Filers
Peter Kolchinsky — 42 joint filings, latest 2009-05-11
RA CAPITAL MANAGEMENT, L.P. — 42 joint filings, latest 2009-05-11
RA Capital Healthcare Fund LP — 41 joint filings, latest 2009-05-11
RICHARD ALDRICH — 32 joint filings, latest 2008-11-21
Advent Global Opportunities Management LLC — same reported address
Advent-NCS Acquisition Limited Partnership — same reported address
CB HEALTHCARE FUND LP — same reported address
Longwood Fund II, L.P. — same reported address
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
BIOSPECIFICS TECHNOLOGIES CORP (BSTC) Delisted 10%+ Owner 826,445 — — $1.57M 2 2009-05-11
SEQUENOM INC (SQNM) Delisted 10%+ Owner 5,472,516 — — $7.19M 3 2008-06-27

Recent Filings

5 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2009-05-11 BIOSPECIFICS TECHNOLOGIES CORP (BSTC) Delisted Buy (P) +63,036 $1.23M EDGAR
2009-03-12 BIOSPECIFICS TECHNOLOGIES CORP (BSTC) Delisted Buy (P) +18,600 $344.9K EDGAR
2008-06-27 SEQUENOM INC (SQNM) Delisted Buy (P) +128,740 $1.86M EDGAR
2008-06-27 SEQUENOM INC (SQNM) Delisted Buy (P) +96,345 $1.55M EDGAR
2008-06-13 SEQUENOM INC (SQNM) Delisted Buy (P) +299,150 $3.77M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.